Fluorinated dendrimer for TRAIL gene therapy in cancer treatment

Area of Science:

• Biotechnology
• Gene Therapy
• Nanomedicine

Background:

• Gene therapy using tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) shows promise for cancer treatment.
• Current TRAIL gene delivery methods face challenges with low transfection efficiency and high vector toxicity.

Purpose of the Study:

• To evaluate a novel fluorinated dendrimer (G4-F7₃₅) as a safe and effective vector for TRAIL gene delivery in cancer therapy.
• To compare the efficacy and toxicity of G4-F7₃₅ with existing transfection reagents.

Main Methods:

• Developed a fluorinated poly(amidoamine) dendrimer (G4-F7₃₅) for gene delivery.
• Transfected cancer cells with plasmid encoding TRAIL (pTRAIL) using G4-F7₃₅ and other reagents (PEI, SuperFect, Lipofectamine 2000).
• Assessed transfection efficacy, cell apoptosis, multicellular spheroid destruction, and in vivo tumor growth suppression.

Main Results:

• G4-F7₃₅ demonstrated significantly higher TRAIL gene transfection and cancer cell apoptosis efficacy compared to PEI, SuperFect, and Lipofectamine 2000.
• The G4-F7₃₅/pTRAIL complex effectively destroyed multicellular spheroids and suppressed tumor growth in vivo.
• G4-F7₃₅ exhibited minimal in vitro toxicity and undetectable systemic toxicity in vivo.

Conclusions:

• Fluorinated dendrimers, specifically G4-F7₃₅, represent a highly effective and low-toxicity vector for TRAIL gene therapy.
• This novel dendrimer vector shows significant potential for advancing clinical applications of cancer gene therapy.